subject: Morning Stock Alert! From Pennytobuck.com - Pwrm, Chdx, Cigna, Cxdc [print this page] ___ ___
Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, reported that Power3 delivered four poster presentations at the 2010 International Conference on Alzheimers Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, Power3s diagnostic test, and focused on Power3s Alzheimers disease blood serum biomarkers, test and clinical validation trials.
According to recent estimates, as many as 2.4 million to 4.5 million Americans have Alzheimers disease (AD). Unless the disease can be effectively treated or prevented, the number of people with AD will increase significantly if current population trends continue. Thats because the risk of AD increases with age, and the U.S. population is aging. The number of people age 65 and older is expected to grow from 39 million in 2008 to 72 million in 2030, and the number of people with AD doubles for every 5-year interval beyond age 65.
Power3 has filed several patent applications for its NuroPro technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimers disease, Parkinsons disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrigs disease).
Last Trade: 0.0270
Change: 7.57%
Volume: 62,100
To learn more about PWRM visit: http://www.power3medical.com
********************
Chindex International, Inc. ("Chindex") (Nasdaq:CHDX), a leading independent American provider of Western healthcare products and services in the People's Republic of China, announced recently that it participated in the following conferences:
-- Morgan Stanley Global Healthcare Conference, on September 13-14, 2010 at the Grand Hyatt Hotel in New York, NY. Management presented at 3:20 pm ET on Tuesday, September 14, and met with institutional investors throughout the day.
-- Morgan Stanley China Global Healthcare Day, on September 15, 2010 at the Taj Boston Hotel in Boston, MA. Management met with institutional investors throughout the day.
On August 27, Chindex International and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"), a leading manufacturer and distributor of western and Chinese medicine and devices in China, announced that they have consummated a previously-announced stock sale.
The closing is part of the strategic alliance between Fosun Pharma and Chindex to form Chindex Medical Limited (the "Joint Venture"), a joint venture focused on manufacturing and distributing medical devices in China. The Joint Venture would merge and operate Chindex's Medical Products division and certain of Fosun Pharma's medical device businesses in China. The Joint Venture would be owned 51% by Fosun Pharma and 49% by Chindex. The closing of the Joint Venture is subject to the final negotiation and execution of definitive documents.
Chindex is an American health care company that provides health care services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Health care services are provided through the operations of its United Family Healthcare division, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in Beijing, Shanghai and Guangzhou. Chindex sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. Chindex was founded in 1981 by Roberta Lipson and Elyse Beth Silverberg, two young American women who had moved to China in the late 1970s, following re-establishment of diplomatic and commercial relations between the US and China, to establish a cross-cultural bridge in the early days of Chinas commercial opening to the West. Their vision was to bring all varieties of advanced Western healthcare technologies to China and provide excellent customer service to buyers and suppliers alike. Their motivation went well beyond the bottom line, to improving the lives of Chinese people.
********************
A.M. Best Co. has assigned a financial strength rating of A (Excellent) and an issuer credit rating of a to CIGNA Health and Life Insurance Company (CHLIC) (Bloomfield, CT), a subsidiary of Connecticut General Life Insurance Company (CGLIC), which is an indirect wholly owned subsidiary of CIGNA Corporation (CIGNA) [NYSE: CI]. The outlook assigned to both ratings is negative.
The ratings of CHLIC are based on its strong capital position and the implicit support of CGLIC. Additionally, the favorable rating implications include a transition plan to move selected CGLICs mid-sized market segment clients into CHLIC, along with the business growth from actively marketing new business beginning in 2011.
Offsetting these favorable factors is the concentration risk of managing a narrow range of business, as CHLIC will focus primarily on the mid-sized market segment. CHLIC will need to file products and/or rates in each of the states in which it intends to compete, which may pose regulatory risks. Furthermore, there are risks associated in transitioning the existing business from CGLIC to CHLIC.
The negative outlook reflects the rating outlook of CHLICs intermediate parent, CGLIC.
The principal methodology used in determining these ratings is Bests Credit Rating Methodology -- Global Life and Non-Life Insurance Edition, which provides a comprehensive explanation of A.M. Bests rating process and highlights the different rating criteria employed. Additional key criteria utilized include: Rating Health Insurance Companies; Understanding BCAR for Life/Health Insurers; Rating New Company Formations; Assessing Country Risk; and Risk Management and the Rating Process for Insurance Companies. Methodologies can be found at www.ambest.com/ratings/methodology
**********************************
China XD Plastics Company Limited ("China XD Plastics" or the "Company"), (Nasdaq: CXDC), one of the leading Chinese manufacturers engaged in the development, manufacture, and distribution of modified plastics primarily for use in automotive applications in China, reported in July that as part of an exclusive product development agreement, it has delivered to Hafei Dongyang ("HD"), one of the leading automotive parts suppliers in Northeast China, three tons of specialized plastic compounds to be used in the battery casing during a pilot production for electric vehicles. In addition, China XD Plastics will have the opportunity to receive additional exclusive product development rights for a period of five years upon the successful design of new specialized plastic products to be used in HD's plastics parts in electric vehicles.
As one of the leading automotive parts suppliers in Northeast China, HD is a supplier of electric vehicle parts to China Changan Harbin Hafei Automobile Industry Group Co., LTD, one of the major auto OEMs in China. According to the agreement, China XD Plastics will, from time to time over the next five years, supply HD with specialized plastics to be used in a wide range of components, including battery cases, cell cases, separators, membranes, polymer super capacitors, composite bipolar plates, silicon wafer carriers, and plastics parts used in charging stations and other applications.
Due to the energy efficiency and environmental advantages of electric vehicles, the Chinese government has made the development of the domestic electric vehicle industry a key priority, supported by a number of programs and policies to foster the growth of this market. According to Mr. Gang Wan, the minister of The Chinese Ministry of Science and Technology, it is expected that electric vehicles will account for at least 10% of total automobiles manufactured in China by 2012 and 50% by 2030, which represents 19.5 million units per year.
China XD Plastics through its operating subsidiaries focuses on the development, manufacture, and distribution of modified plastics primarily for the use in automotive applications. The company's history can be traced back to 1985.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares as compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings Inc. had received an additional amount of 2,000,000 shares of free trading stock for 60 days of media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB). Each advertising commitment has now expired
